

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/214339 A2

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/IB2023/054620
- (22) **International Filing Date:**
03 May 2023 (03.05.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/338,878 05 May 2022 (05.05.2022) US
63/499,276 01 May 2023 (01.05.2023) US
- (71) **Applicant: PFIZER INC.**, [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).
- (72) **Inventors: AL-LOZI, Amer**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **BHATTACHARYA, Keshab**; 8901 White Avenue, Brentwood, Missouri 63144 (US). **DONG, Guogang**; c/o Pfizer Inc., 1 Burt Road, Andover, Massachusetts 01810 (US). **GHOSH, Swapnadip**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **JHUN, Hugo**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **MORAN, Justin Keith**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **PATEL, Urmi Ankit**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **QUAGLIA MOTTA, Jennifer Julia**; c/o Pfizer Inc., 1 Burt Road, Andover, Massachusetts 01810 (US). **RUSSO, Joseph**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **SHOPERA, Tatenda**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **SIMMS, Carrie Leanne**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **SINANAN, Dillon Jarod**; c/o Pfizer Inc., 1 Burt Road, Andover, Massachusetts 01810 (US). **VANDE VOORDE, Michael Casey**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **WILLIAMSON, Jenna Kathryn**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **WOOD, Nichole Lea**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **ZHENG, Xiaolu**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **ALLEN, Martin John**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **ALLISON, Daniel Ward**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US).

souri 63017 (US). **ARMOUR, Kaley Elizabeth**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **BREEN, Shelby Hutchins**; 10 Lorraine Avenue, North Andover, Massachusetts 01845 (US). **KIM, Sun Joong**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **RAMESH, Athreya Subramanian**; of c/o Pfizer Inc., 1 Burt Road, Andover, Massachusetts 01810 (US). **REEVES, Erin Courtney**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **SMITH, Karennia Caroline**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US). **SWYERS, Michael Jay**; c/o Pfizer Inc., 875 Chesterfield Parkway W., Chesterfield, Missouri 63017 (US).

(74) **Agent: ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) **Title:** METHODS FOR PRODUCING NUCLEIC ACIDS

(57) **Abstract:** Described are methods for producing RNA molecules in an in vitro transcription reaction. Also described are methods for producing an mRNA molecule from a circular double-stranded DNA template using an in vitro transcription reaction system wherein the in vitro transcription reaction system lacks a polyamine. Also described are in vitro transcription reaction systems comprising enzymatic 5' capping and oligo(dT) purification.



WO 2023/214339 A2

[Continued on next page]

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*